Antibody humanization
Humanize your antibodies with a success rate of more than 98%.
Our team can help you humanize monoclonal antibodies from a wide range of species, including mice, hamsters, rats, rabbits, chickens and camelids.
We design unlimited variants, working with you to generate lead antibodies with the best chance of reaching clinical trials.
All at no cost to you – instead, we receive a single digit royalty on future sales.
Humanized antibodies for 5 market-approved drugs
What you’ll get from partnering with us
No cost to you
We take on the risk, so you don’t have to. In return, we receive a single digit royalty on sales after market approval is secured.
Retain your intellectual property
You retain IP ownership and commercialisation control after the project ends. We can provide follow-on patent support.
Open dialogue and regular sample sharing
Our top scientists work with you to maximise your antibody’s therapeutic potential. You’ll receive humanized antibodies, expression vectors and a comprehensive report in around 7 months.
Unlimited candidates for your success
We consider any target, modality or therapeutic indication and produce as many candidates as we need – we don’t limit ourselves to a fixed number – to get you the best result possible.
Antibodies with the best chance of reaching clinical trials
Lead antibodies have optimal expression levels and binding, stability and biophysical characteristics. Most display a binding level at least 95% that of the chimeric molecule.
Our track record
30
years of experience
94
antibodies humanized
51
partners worldwide, from 13 countries
98%
success rate
Learn more about our antibody discovery and humanization capabilities
Who to contact
-
Preeti Bakrania
Read bio: Preeti Bakrania
Other ways we can support you
Antibody discovery
Innovative single B-cell technologies and clinically-validated platform to generate fully human therapeutic antibodies.
Diagnostics development
We support all stages of diagnostic development, from assay design through to clinical validation.
Targeted protein degradation
PROTACs and alternative E3 ligases to degrade target proteins that aren’t classically targetable by small molecule inhibitors.
Commercialisation advice
Support your technology transfer to progress your work towards commercially viable products.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Latest news
-
Promising results in clinical trial gives hope to patients with blood disorder
-
3 steps LifeArc is taking to tackle antimicrobial resistance before it’s too late
-
£76M investment backing into potential MND treatment, underlines benefit of charity funding